BUSINESS
GSK India posts Rs 255 crore net profit in Q2FY26
Revenue from operations stood at ₹974 crore, reflecting a temporary topline dip due to GST-related transitions, seasonal disruptions, and a fire at a contract manufacturing site that impacted supply of select general medicines brands.
BUSINESS
Sun Pharma backs speciality play, lines up launches in US amid uncertainty over tariffs
Despite macro uncertainties, Sun Pharma has been bullish on its specialty pipeline and global expansion.
BUSINESS
Syngene net profit drops 37% to Rs 67 crore in Q2FY26
“Our Q2 performance was driven by underlying revenue growth from research services which compensated for the anticipated inventory correction in biologics manufacturing,” said Peter Bains, Managing Director and CEO.
BUSINESS
Piramal Pharma posts Rs 99 crore loss in Q2FY26 weighed down by CDMO business
The company attributed the loss to decline to inventory destocking by a key customer in a large on-patent CDMO order and slower order inflows amid inconsistent recovery in US biopharma funding.
BUSINESS
Sun Pharma net profit rises 2.6%YoY to Rs 3,118 crore in Q2FY26
Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) geographies.
BUSINESS
Gland Pharma net profit rises 12%YoY to Rs 183.7 crore in Q2FY26
Consolidated revenue rose 6% to ₹1487 crore, while EBITDA grew 6% to ₹313.9 crore.
BUSINESS
Dr.Ajaikumar-backed Inviga Healthcare Fund picks up 21% stake in Forus Health
Forus Health, best known for its 3nethra series of eye screening devices, has screened over 22 million patients across 75 countries.
BUSINESS
Wockhardt swings to profit in Q2, novel antibiotic Zaynich gets breakthrough status in Saudi Arabia
Revenue for the quarter stood at ₹782 crore, up from ₹738 crore in Q1. EBITDA margins improved to 20.5%, up from 13.7% in the previous quarter.
BUSINESS
Narayana Health targets 22% RoCE by FY30 in UK bet, eyes private pay growth to boost margins
The Indian hospital chain, known for its low-cost, high-throughput model, is entering the UK market through its Cayman Islands subsidiary, acquiring the secondary care division of Practice Plus Group — the fifth-largest private healthcare network in the UK and fourth-largest NHS service provider.
BUSINESS
Medikabazaar co-founder alleges Rs 264 crore fraud in FIR against board and investors
In a complaint registered by Mumbai’s Economic Offences Wing (EOW) on October 30, Tiwari accused directors from Creaegis, Healthquad, and Ackerman Van Haaren of diverting company funds to non-existent entities
BUSINESS
Lupin stands tall in digital therapeutics as others struggle
Unlike competitors that rushed to market, Lupin spent its early years conducting trials and publishing peer-reviewed studies — a strategy that CEO Sidharth Srinivasan says has been key to survival.
BUSINESS
Narayana Health buys UK’s Practice Plus for Rs 1,930 crore to expand global footprint
The acquisition gives Narayana Hrudayalaya a strategic entry into the mature UK healthcare market, which is witnessing a shift toward day-care procedures and increased private-pay penetration.
BUSINESS
Fertility startup Pluro raises Rs 125 crore in Series A round led by Bessemer, valuing the firm at Rs 1,000 crore
The latest funding round valued the startup at Rs 1,000 crore and saw participation from prominent angel investors including Vikram Chatwal (MediAssist), Dharmil Sheth and Hardik Dedhia (PharmEasy), and Salil Musale (Astarc Ventures).
BUSINESS
Umang Vohra, Cipla’s outgoing CEO says task achieved, ‘not retiring’ from sector
Vohra was the second executive roped in from outside Cipla’s promoter family to lead the drug maker. Under his watch, Cipla saw a sharp improvement in profitability, driven by strategic expansion in chronic therapies, operational efficiencies and global partnerships.
BUSINESS
Cipla sees ‘material opportunity’ in Mounjaro deal, eyes deeper reach across India
The company sees no supply constraints for tirzepatide, a concern that has plagued other players in the GLP-1 space globally.
BUSINESS
Dr Reddy’s warns of 'huge monetary loss' in plea against FSSAI order on ORS
According to the petition, Dr Reddy’s has around 8.47 lakh units of unsold Rebalanz VITORS across its apple, orange and mango variants, with a total realisable value of Rs 1.39 crore, as of October 15
BUSINESS
Thermo Fisher invests Rs 160 crore to expand Bengaluru R&D centre
The expansion is expected to create over 100 high-skilled jobs in the coming years.
BUSINESS
Manipal Group-backed Stempeutics bags first of its kind stem cell treatment deal in Japan
Medinet will develop and commercialize Stempeucel in Japan, pending regulatory clearance, and receive an upfront payment with additional milestone and royalty if the Tokyo-listed firm exercises the option to license the product
BUSINESS
How Eli Lilly’s weight-loss drug Mounjaro gained early lead against Novo Nordisk’s Wegovy in India
Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical performance and early entry advantage.
BUSINESS
Dr Reddy’s bets on three key launches to offset US price erosion
“Semaglutide, denosumab and abatacept are the three molecules that will help us mitigate the impact of declining Revlimid sales and bring back growth momentum,” said M.V. Narasimham, Chief Financial Officer, in a post-earnings interview.
BUSINESS
Eli Lilly allows Cipla to sell weight loss drug 'Tirzepatide' under new brand in India
Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro, launched earlier this year.
BUSINESS
Laurus Labs posts Rs 195 crore net profit in Q2FY26 led by CDMO, generics momentum
The surge in profitability was underpinned by a 35% rise in revenues to ₹1,653 crore and a 136% jump in EBITDA to ₹429 crore, lifting margins to 26% from 14.9% a year earlier.
BUSINESS
Indian CRDMOs eye growth as US Biosecure Act and US-China trade tensions may redraw supply chains
India’s CRDMO sector, currently valued at $3–3.5 billion, accounts for just 2–3% of the $140–145 billion global market. But with a 15% CAGR from 2019 to 2024—double the global average—the industry is at an inflection point.
BUSINESS
RPG Life Sciences eyes strategic acquisitions as cash-rich balance sheet fuels expansion plans
The pharma firm, part of the RPG Group, is leveraging its robust balance sheet to explore inorganic growth across APIs, formulations, and emerging therapeutic trends.
